All device, diagnostic, and digital startups are encouraged to apply to MedTech Innovator at https://medtechinnovator.org/apply. Additionally, the following list highlights technologies identified as specifically of strategic interest via our medtech industry survey.
Our interests are not limited to this list, but if you know a company that matches any of the below interest areas, please encourage them to apply and/or nominate them directly at http://bit.ly/2sU2WGH.
Disrupts an existing drug market with an unmet need
Minimally invasive surgical tools
Innovative safety mechanisms
Automated cell culture equipment and systems
REMOTE PATIENT MONITORING AND CLINICAL STUDIES
Measure relevant biometric & behavior parameters
With/without clinical decision support
ADDITIONAL INTEREST AREAS
U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
MedTech Innovator is sourcing opportunities in partnership with US military for a military pitch event to be held in February. The following list highlights technologies identified as specifically of interest by the US Military for this event. If you know a company that matches any of these interest areas, then please encourage them to apply at https://medtechinnovator.org/apply.
|MEDICAL SIMULATION (MEDSIM):|
|ARTIFICIAL INTELLIGENCE IN MEDICAL SCIENCES (AIMS):|
Artificial intelligence for real-time medical command awareness in multi-domain operations
|MEDICAL ASSIST SUPPORT TECHNOLOGIES (MAST):|
|CLINICAL AND REHABILITATIVE MEDICINE:|
Technology Objectives: The Clinical and Rehabilitative Medicine Research Program has identified a need for regenerative medicine prototype development efforts and manufacturing technologies. Current Good manufacturing practice (cGMP) quality is a requirement by the FDA and European Medicines Agency to provide patients with clinical-grade products that are safe and have defined quality characteristics. However, standardization and robust manufacturing techniques are lacking in regenerative medicine, which will continue to impede progress in advancing regenerative medicine based technologies and treatments toward the clinic. This is likely due to many factors which need to be developed and advanced, including 1) Processing technologies for Quality Management of acellular matrices or Stem Cell (SC)-derived cell based therapies. 2) Manufactured Universal Acellular Matrix 2) Innovative Manufacturing Process for SC-Derived Cell Based Therapies. Based on this, the major objective of this effort is to develop solutions for quality management of prototypes and processes for cell, tissue, or organ bioengineering technologies that will overcome current challenges and enable successful cGMP manufacturing and clinical translation of regenerative medicine based therapies.
Technologies of interest include the following:
|MILITARY OPERATIONAL MEDICINE:|
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
MedTech Innovator was selected by BARDA to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. If you know a company that matches the interests below, please encourage them to email firstname.lastname@example.org and apply at https://www.drive.hhs.gov/partner.html?id=applyNow and reference MedTech Innovator as the source of the application.
Sepsis is one of the country’s most urgent systemic health threats. Each year, more than 1.5 million people in the U.S. get sepsis. Sepsis kills a quarter-million Americans each year. Sepsis can occur when a trauma or an infection – often caused by a superbug or drug-resistant bacteria in the skin, lungs or kidney (urinary tract) – triggers a chain reaction throughout the body. Without timely recognition and treatment, it can rapidly cause tissue damage, organ failure, and death. One in three patients who die in a hospital have sepsis. Read more about sepsis.
DRIVe is seeking bold solutions to solve sepsis. These include innovations focused on:
Clinical management strategies supported by enhanced education and awareness
Rapid diagnostics & prognostics
Continuous multi-dimensional patient monitoring
Machine learning-based disease management feedback algorithms
Optimized therapeutic interventions
Too often, people do not receive adequate and timely treatment for infectious diseases like influenza. We either do not seek care, or do so many days late, leading to severe illness, and transmission of infectious agents within the household, at the workplace. Early Notification to Act, Control, and Treat (ENACT) will disrupt the traditional clinical care paradigm of healthcare outside of the home (within a physician’s office, urgent care center, or hospital). It will rapidly leverage the power of transformational technologies to empower individuals to be aware of their own health status and to take action.
DRIVe seeks solutions that:
Leverage advanced data analytics and algorithms coupled with innovative detection modalities to accurately and quickly diagnose patients who have been exposed to pathogens and prognosticate outcomes
Close the gap between diagnosis and treatment by utilizing the power of telemedicine to bring clinical care into the home
Empower people, to give them a greater role in their health outcomes. Looking for biological, biometric, behavioral, and physiological technologies and approaches to identify threats and challenges and put in place systems to mitigate the harm.
Better ways to detect threats, point-of-use indicators, biological and physiological sensing technologies